<DOC>
	<DOCNO>NCT01828346</DOCNO>
	<brief_summary>This dose escalation follow dose expansion study TL32711 combination 5-Azacitidine subject Myelodysplastic syndrome naïve , relapse failed prior 5-azacitidine therapy . Pre-clinical mechanistic study support 5-Azacitidine may modulate pathway enable birinapant-mediated anti-tumor activity .</brief_summary>
	<brief_title>Birinapant With 5-azacitidine MDS Subjects Who Are Naïve , Have Relapsed Are Refractory 5-azacitidine Therapy</brief_title>
	<detailed_description>This Phase 1b/2a , open-label , non-randomized study male female subject MDS naïve , refractory relapse 5-Azacitidine therapy . Primary Objective determine maximum tolerate dose ( MTD ) , recommend Phase 2 dose , pharmacodynamics ( PD ) birinapant ( TL32711 ) administer combination 5-azacitidine ( 5 AZA ) subject myelodysplastic syndrome ( MDS ) naïve , refractory relapse 5-AZA therapy . Secondary Objectives determine clinical activity use International Working Group ( IWG ) ( Cheson , 2006 ) Response Criteria MDS Phase 1b dose escalation stage study Phase 2a expansion cohort , determine pharmacokinetics ( PK ) birinapant administer 5-AZA plasma ass exploratory translational biomarkers anti-tumor activity birinapant combination therapy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Men woman 18 year age . Patients highrisk Myelodysplastic Syndrome Performance status great equal 2 Eastern Cooperative Oncology Group ( ECOG ) scale . Subjects highrisk MDS naïve 5Azacitidine previously receive 5AZA decitabine firstline cytotoxic therapy . Subjects prior 5Azacitidine therapy evaluate either refractory relapse determined Investigator , accord IWG response criteria.Subjects relapse refractory disease may receive prior 5Azacitidine decitabine . Hydroxyurea patient rapidly proliferative disease use 24 hour prior therapy concomitantly 5Azacitidine . Adequate liver , pancreatic renal function . Women childbearing potential must negative serum pregnancy test screening within 48 hour prior first dose Women childbearing potential must agree use 2 method adequate contraception Subjects lifethreatening toxicity non tolerability prior 5Azacitidine therapy . Subjects hypoplastic Myelodysplastic syndrome . Subjects &gt; 30 % bone marrow blast cell . Subjects malignant hepatic tumor secondary malignancy within 2 year Known diagnosis human immunodeficiency virus chronic active Hepatitis B C. Uncontrolled hypertension Impaired cardiac function , uncontrolled cardiac arrhythmia despite medication , QT interval correct heart rate ( QTcB ) 480 msec Lack recovery prior adverse event Grade ≤1 severity ( National Cancer Institute Common Terminology Criteria Adverse Events version 4 ) ( except alopecia ) due therapy administer prior initiation study drug dose . Nursing pregnant woman . Known allergy formulation component birinapant . Known suspected hypersensitivity 5Azacitidine mannitol . Any concurrent disease and/or medical condition , opinion Investigator , would prevent subject 's participation . History Bell 's Palsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>TL32711</keyword>
	<keyword>Birinapant</keyword>
	<keyword>5-Azacitidine</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Failed</keyword>
	<keyword>open-label</keyword>
	<keyword>non-Randomized</keyword>
	<keyword>dose-escalation</keyword>
	<keyword>dose-expansion</keyword>
</DOC>